Market Overview

Morgan Stanley Sees Sapien Becoming Leading Product Line for Edwards Lifesciences

Related EW
UPDATE: Morgan Stanley Raises PT On Edwards Lifesciences Corp., Say Upside Now Tied To Bull Case
Credit Suisse Raises 2015 TAVI Estimates for Edwards Lifesciences Corp.
Making Money With Charles Payne: 10/10/14 (Fox Business)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Edwards Lifesciences (NYSE: EW).

In the report, Morgan Stanley noted, “Sapien should prove to be the leading product line in transcatheter valves into '14 and beyond, supported by clinical data. The TAVR market is likely to continue its expansion, supported by better budgets in Europe, favorable clinical data in lower risk populations, and more deliverable products. A mitral replacement program could drive upside given the larger potential patient pool relative to the aortic space. Higher valve revenue mix supports higher GMs.”

Edwards Lifesciences closed on Thursday at $80.27.

Latest Ratings for EW

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014Bank of AmericaMaintainsNeutral
Dec 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (EW)

Around the Web, We're Loving...

Get Benzinga's Newsletters